Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Praziquantel

FDA-approved product (tablet, oral), marketed as Biltricide, Praziquantel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Praziquantel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis
  • Infection
  • Opisthorchiasis
  • Schistosomiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Quinoline derivatives and related substances
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02BA01; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Praziquantel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Praziquantel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oxfendazole in Mild Parenchymal Brain Cysticercosis

    NCT06565507 · start 2026-12-01

    Registered record
    Registry ID
    NCT06565507
    Conditions
    Brain Cysticercosis
    Interventions
    Oxfendazole single dose; Oxfendazole three doses; albendazole plus praziquantel regime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2030-12-15
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Cysticercosis
    InterventionOxfendazole single dose; Oxfendazole three doses; albendazole plus praziquantel regime
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis

    NCT07754617 · start 2026-11

    Registered record
    Registry ID
    NCT07754617
    Conditions
    Schistosomiasis; Schistosoma Mansoni; Liver Fibrosis; Portal Hypertension
    Interventions
    Praziquantel 40 mg/kg per dose given once annually; Praziquantel 40 mg/kg given three times per year
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-11
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis; Schistosoma Mansoni; Liver Fibrosis; Portal Hypertension
    InterventionPraziquantel 40 mg/kg per dose given once annually; Praziquantel 40 mg/kg given three times per year
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations

    NCT07707817 · start 2026-07-01

    Registered record
    Registry ID
    NCT07707817
    Conditions
    Onchocerciasis (River Blindness); Schistosomiasis; Soil Transmitted Helminth (STH) Infections; Lymphatic Filariasis
    Interventions
    Modified Mass Administration of Medicines Strategy; Albendazole 400 mg; Praziquantel 40 mg/kg; Ivermectin; Ivermectin + albendazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-01
    Completion
    2027-11-30
    Enrolment
    5,760

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis (River Blindness); Schistosomiasis; Soil Transmitted Helminth (STH) Infections; Lymphatic Filariasis
    InterventionModified Mass Administration of Medicines Strategy; Albendazole 400 mg; Praziquantel 40 mg/kg; Ivermectin +1 more
    PhaseNot applicable
    Registry statusRecruiting

  • Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

    NCT07074444 · start 2025-07-22

    Registered record
    Registry ID
    NCT07074444
    Conditions
    Clonorchiasis
    Interventions
    Albendazole; Tribendimidine; praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-22
    Completion
    2026-12-31
    Enrolment
    318

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClonorchiasis
    InterventionAlbendazole; Tribendimidine; praziquantel
    PhasePhase 4
    Registry statusRecruiting

  • Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

    NCT06376396 · start 2024-06

    Registered record
    Registry ID
    NCT06376396
    Conditions
    Neurocysticercosis
    Interventions
    albendazole and praziquantel; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-06
    Completion
    2026-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis
    Interventionalbendazole and praziquantel; Albendazole
    PhasePhase 4
    Registry statusNot yet recruiting

  • Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control

    NCT06182176 · start 2024-05-27

    Registered record
    Registry ID
    NCT06182176
    Conditions
    Malaria; Soil Transmitted Helminths; Schistosomiasis; Seasonal Malaria Chemoprevention; Mass Drug Administration With Anthelminthic Drugs
    Interventions
    Sulphadoxine-pyrimethamine and Amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-05-27
    Completion
    2026-01-12
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Soil Transmitted Helminths; Schistosomiasis; Seasonal Malaria Chemoprevention +1 more
    InterventionSulphadoxine-pyrimethamine and Amodiaquine
    PhaseNot applicable
    Registry statusUnknown

  • HIV And Parasitic Infection (HAPI) Study

    NCT05323396 · start 2022-05-02

    Registered record
    Registry ID
    NCT05323396
    Conditions
    HIV Coinfection
    Interventions
    Antiparasitic medication
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-05-02
    Completion
    2023-08-04
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Coinfection
    InterventionAntiparasitic medication
    PhaseNot applicable
    Registry statusCompleted

  • Adoption of L-PZQ for Schistosomiasis by Endemic Counties - Social Science Research Study

    NCT05350462 · start 2021-12-01

    Registered record
    Registry ID
    NCT05350462
    Conditions
    Schistosomiasis in Children; Social Acceptance
    Interventions
    Community pilot L-PZQ distribution - intervention is NOT part of this observational study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2025-12-31
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis in Children; Social Acceptance
    InterventionCommunity pilot L-PZQ distribution - intervention is NOT part of this observational study
    PhaseNot recorded
    Registry statusUnknown

  • Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni

    NCT04679831 · start 2021-05-06

    Registered record
    Registry ID
    NCT04679831
    Conditions
    Schistosoma Mansoni
    Interventions
    Ujiplus®; Praziquantel 400mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-05-06
    Completion
    2022-03-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosoma Mansoni
    InterventionUjiplus®; Praziquantel 400mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Praziquantel in Children Under Age 4

    NCT03640377 · start 2021-02-01

    Registered record
    Registry ID
    NCT03640377
    Conditions
    Schistosomiasis; Schistosomiasis Mansoni; Schistosoma Japonicum Infection
    Interventions
    Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-02-01
    Completion
    2024-06-01
    Enrolment
    354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis; Schistosomiasis Mansoni; Schistosoma Japonicum Infection
    InterventionPraziquantel
    PhasePhase 2
    Registry statusCompleted

  • Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide

    NCT04314037 · start 2020-06-17

    Registered record
    Registry ID
    NCT04314037
    Conditions
    Healthy
    Interventions
    Cesol (Test); Biltricide (Reference)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-17
    Completion
    2020-07-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCesol (Test); Biltricide (Reference)
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

    NCT03893097 · start 2019-10-14

    Registered record
    Registry ID
    NCT03893097
    Conditions
    Schistosoma Haematobium; Schistosoma Mansoni
    Interventions
    Praziquantel; Artesunate + Mefloquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-14
    Completion
    2021-03-04
    Enrolment
    726

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosoma Haematobium; Schistosoma Mansoni
    InterventionPraziquantel; Artesunate + Mefloquine
    PhasePhase 3
    Registry statusCompleted

  • L-PZQ ODT in Schistosoma Infected Children

    NCT03845140 · start 2019-09-02

    Registered record
    Registry ID
    NCT03845140
    Conditions
    Schistosomiasis
    Interventions
    L-PZQ ODT 50 mg/kg; Biltricide®; L-PZQ ODT 60 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-02
    Completion
    2021-10-11
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    InterventionL-PZQ ODT 50 mg/kg; Biltricide®; L-PZQ ODT 60 mg/kg
    PhasePhase 3
    Registry statusCompleted

  • Schistosomiasis Diagnosis Using a CAA Antigen Test

    NCT03779347 · start 2019-05-01

    Registered record
    Registry ID
    NCT03779347
    Conditions
    Schistosomiasis Hematobium; Diagnostic; Drug Reaction; Pregnancy
    Interventions
    Praziquantel; UCP-LF CAA; composite diagnostic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-05-01
    Completion
    2022-05-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis Hematobium; Diagnostic; Drug Reaction; Pregnancy
    InterventionPraziquantel; UCP-LF CAA; composite diagnostic
    PhasePhase 3
    Registry statusUnknown

  • Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

    NCT03799510 · start 2018-12-13

    Registered record
    Registry ID
    NCT03799510
    Conditions
    Schistosomiasis
    Interventions
    Sm14; GLA-SE solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-12-13
    Completion
    2019-08-07
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    InterventionSm14; GLA-SE solution
    PhasePhase 2
    Registry statusCompleted